Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

noCOLDmore

Financiado

Reprogramming eNdOthelial cells in immune-COLD tuMORs

Lung cancer is the leading cause of cancer-related deaths worldwide. Currently, immunotherapy (IT) is the standard of care for the treatment of some subtypes, with only nominal success. IT works best in inflamed hot tumors and is... ver más

31/01/2027

VLAAMS INSTITUUT...

176K€

Presupuesto del proyecto: 176K€

Líder del proyecto

VIB VZW No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-03-11

HORIZON-MSCA-2023-PF-01-01: MSCA Postdoctoral Fellowships 2023 ExpectedOutcome:Project results are expected to contribute to the following outcomes:

I+D

Cerrada hace 1 año

0% 100% 100%

1 Participantes

VLAAMS INSTITUUT BIOTECHNOL...

175.92K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2021-122741OB-I00 IDENTIFICACION DE NUEVAS OPORTUNIDADES TERAPEUTICAS CAUSADAS... 230K€ Cerrado

DETECTIVE DEmystifying Targets in Endothelial Cells for anti-Tumor Imm... 192K€ Cerrado

PLEC2021-007959 USO DE LA INHIBICIÓN DE MYC PARA SUPERAR LA RESISTENCIA A LA... 378K€ Cerrado

RTI2018-094507-B-I00 MECANISMOS DE METASTASIS EN EL CANCER DE PULMON 182K€ Cerrado

EUIN2017-87851 INTEGRACION DE OMICAS PARA LA TERAPIA DIRIGIDA EN INMUNOTERA... 10K€ Cerrado

RTI2018-099161-A-I00 MECANISMOS MOLECULARES REGULADOS POR RAS-PI3K DURANTE LA INT... 157K€ Cerrado

Duración del proyecto: 34 meses Fecha Inicio: 2024-03-11
Fecha Fin: 2027-01-31

Líder del proyecto

VIB VZW No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 176K€

Descripción del proyecto Lung cancer is the leading cause of cancer-related deaths worldwide. Currently, immunotherapy (IT) is the standard of care for the treatment of some subtypes, with only nominal success. IT works best in inflamed hot tumors and is often ineffective in immune cell-desert cold tumors. In KRAS-mutated lung adenocarcinoma -LUAD, the most frequent type of lung cancer- the presence of a mutation in the STK11/LKB1 gene is linked to a cold tumor, while the co-occurrence of a TP53 mutation corresponds to a hot tumor. Amongst different cell types in the tumor environment impacting immune cell composition, endothelial cells (ECs) present an important and often overlooked modulator of immune profiles. Previous research has identified immunoregulatory genes expressed by ECs and proposed immuno-modulatory roles of ECs. I hypothesize that specific mutations cause the expression of immunosuppressive genes by ECs, which might explain the association of gene mutations affecting the immune environment. Thus, modulating ECs to reprogram them into immunostimulatory phenotypes in the immune cold tumors, could present a promising strategy to improve IT responses. To identify the immunosuppressive gene signature in ECs in immune cold vs hot tumors, I will utilize transgenic mouse models of LUAD: KrasG12D/+; Lkb1flox/flox (KL) and KrasG12D/+; Tp53flox/flox (KP) mice. First, using scRNAseq, I will establish an EC signature linked to the immune cold tumors and subsequently to identify EC-specific candidate immunosuppressive targets. After that, I will use state-of-the-art technologies that enable efficient gene targeting to validate the discovered targets in KL mice. I perform multidisciplinary approaches to delineate the molecular mode of action of the target exhibiting a substantial therapeutic effect in mice and overcoming the resistance to current anti-cancer IT. Finally, I will employ a humanized orthotopic lung PDX mouse model to further validate and test therapeutic opportunities.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores